Halper Sadeh Targets Soleno Therapeutics $53 Per Share Sale to Neurocrine
Soleno Therapeutics shareholders could challenge its $53 cash sale to Neurocrine, claiming insiders may receive outsized benefits and deal terms could deter competing bids. Halper Sadeh LLC is investigating, offering contingent-fee legal representation to seek higher consideration or additional disclosures.
1. Sale Agreement Terms
Soleno Therapeutics has agreed to be acquired by Neurocrine Biosciences in an all-cash transaction valued at $53 per share. The merger agreement outlines the deal structure and expected timeline for completion pending regulatory and shareholder approval.
2. Legal Investigation
Halper Sadeh LLC is investigating whether this transaction breaches fiduciary duties by potentially granting insiders disproportionate financial benefits and including deal protections that could deter competing offers.
3. Shareholder Options
Shareholders are being invited to discuss their rights and potential legal claims on a contingent-fee basis with no upfront costs, aimed at seeking increased consideration or additional disclosures before finalizing the deal.